Biomed 101

Biomed 101 An agent binding to the leukotriene B4 receptor. This lead's to reduce levels of interleukin-2 mediated hypoxia. Biomed 101 does not affect interleukin-2 antitumor activity.

Biomed 101 is also in the process of being tested to see if it can help reduce the side effects of a drug called interleukin-2 (IL-2), al ready it has been found that Biomed 101 does not affect interleukin-2 antitumor activity meaning these two drugs can work to gather safely if the anti-side effect property is found within Biomed 101.

References

- National Cancer Institute (NCI Drug Dictionary)